Vehicle control system and method, and component devices
    2.
    发明授权
    Vehicle control system and method, and component devices 有权
    车辆控制系统和方法以及组件设备

    公开(公告)号:US08138894B2

    公开(公告)日:2012-03-20

    申请号:US11972381

    申请日:2008-01-10

    IPC分类号: G05B19/00 G08C19/12 H04B7/00

    CPC分类号: B60R25/24 B60R25/2072

    摘要: An in-vehicle device notifies a mobile device of a frequency channel which has been stored in its memory unit, and sets the notified channel to a reception channel. The mobile device transmits a reply signal through the channel notified from the in-vehicle device. When the in-vehicle device determines that a code included in the received reply signal is identical with a code specific to a vehicle, the in-vehicle device stores the channel used for receiving the reply signal in its memory unit. As a result, each communication is conducted through the same channel, which enabled the successful communication previously, thereby enhancing the certainty of communication.

    摘要翻译: 车载设备向移动设备通知已经存储在其存储单元中的频道,并将所通知的频道设置为接收频道。 移动装置通过从车载装置通知的频道发送应答信号。 当车载设备确定包括在接收到的应答信号中的代码与车辆特有的代码相同时,车载设备将用于接收回复信号的信道存储在其存储单元中。 结果,每个通信通过相同的信道进行,这使得先前成功地通信,从而增强了通信的确定性。

    Nitrocarburized crankshaft member and steel for nitrocarburized crankshafts
    4.
    发明授权
    Nitrocarburized crankshaft member and steel for nitrocarburized crankshafts 有权
    用于氮碳共渗曲轴的碳氮共渗曲轴构件和钢

    公开(公告)号:US08911566B2

    公开(公告)日:2014-12-16

    申请号:US12958855

    申请日:2010-12-02

    IPC分类号: F16C3/06 B21K1/08

    摘要: A nitrocarburized crankshaft member made of a steel that includes C in an amount by weight of 0.25 to 0.32% as a required element and an optional element that may be included, and Fe and inevitable impurities in a remaining portion. The steel-made crankshaft member mainly includes ferrite and perlite, wherein at least a portion of the steel surface thereof having a ferrite surface area of 50% or greater is imparted with a nitrocarburized hard layer. The nitrocarburized hard layer includes a surface compound layer suppressed to a thickness of 10 to 35 μm, and a nitrogen diffusion zone below the surface compound layer having a diffusion depth of 700 μm or greater. The steel includes C, Si, Mn, Cu, Ni, and Cr as the required elements and Mo, N, s-Al, and Ti as the optional elements.

    摘要翻译: 由钢制成的氮碳共渗曲轴构件,其包含作为所需元素的重量为0.25〜0.32%的C和可以包含的任选元素,剩余部分中的Fe和不可避免的杂质。 钢制曲轴构件主要包括铁素体和珍珠岩,其中具有铁素体表面积为50%以上的钢表面的至少一部分被赋予了氮碳共渗硬化层。 氮碳共渗硬化层包括被抑制为10〜35μm厚度的表面化合物层和扩散深度为700μm以上的表面化合物层下方的氮扩散区。 钢包含C,Si,Mn,Cu,Ni和Cr作为所需元素,Mo,N,s-Al和Ti作为任选元素。

    Antagonistic Human LIGHT-Specific Human Monoclonal Antibodies
    5.
    发明申请
    Antagonistic Human LIGHT-Specific Human Monoclonal Antibodies 有权
    拮抗人类LIGHT特异性人类单克隆抗体

    公开(公告)号:US20120076798A1

    公开(公告)日:2012-03-29

    申请号:US13240356

    申请日:2011-09-22

    摘要: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

    摘要翻译: 本文提供了免疫特异性结合于hLIGHT多肽的抗体; 编码抗体的分离的核酸; 载体和宿主细胞,其包含编码抗体的核酸; 制备抗体的方法; 以及治疗受试者中的hLIGHT介导的疾病的方法,包括向受试者施用抗体。 在优选的实施方案中,本文提供的抗hLIGHT抗体将改善,中和或抑制体内的hLIGHT生物活性(例如,hLIGHT介导的来自表达hLIGHT受体的细胞的CCL20,IL-8或RANTES的产生或分泌)。 本文还提供了用于检测样品中的hLIGHT的方法以及用于改善,中和或抑制hLIGHT活性的方法,例如在患有hLIGHT活性有害的病症的人类受试者中。

    Treating amnesia with a pyrrolidone derivative
    8.
    发明授权
    Treating amnesia with a pyrrolidone derivative 失效
    用吡咯烷酮衍生物治疗遗忘

    公开(公告)号:US4833156A

    公开(公告)日:1989-05-23

    申请号:US160600

    申请日:1988-02-26

    CPC分类号: A61K31/635 A61K31/40

    摘要: A use of the pyrrolidone derivative represented by the following formula [I] as an anti-amnesitc agent: ##STR1## wherein R represents a group ##STR2## X represents --SO.sub.2 -- or --CO--; R' represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom or a nitro group; n denotes an integer of 1-5; and, when n is an integer of 2 or more, R' may be the same or different, provided that(a) when X is --SO.sub.2 --, there is no case where R' is 3-CF.sub.3, 4-Cl-5-CF.sub.3, 3,5-(CF.sub.3).sub.2 or 3-NO.sub.2 ;(b) when X is --CO--, there is no case where n denotes 1 or 2 and R' is a halogen atom or a nitro group;(c) when X is --SO.sub.2 --, there is no case where n denotes 1 or 2 and R' is a group other than 4-Cl or 3-NO.sub.2 ; and(d) when n denotes 2, there is no case where the groups R' represent the same group which is halogen atom or a nitro group.Typical pyrrolidone derivatives are N-(4'-toluene-sulfonyl)-2-pyrrolidone, N-(4'-chlorobenzenesulfonyl)-2-pyrrolidone, N-benzenesulfonyl-2-pyrrolidone and N-[4'-(1", 1"-dimethylethyl)benzoyl]-2-pyrrolidone, particularly N-(4'-chloro-benzenesulfonyl)-2-pyrrolidone.

    Manufacturing method for a crankshaft member
    9.
    发明授权
    Manufacturing method for a crankshaft member 有权
    曲轴构件的制造方法

    公开(公告)号:US08685177B2

    公开(公告)日:2014-04-01

    申请号:US12630536

    申请日:2009-12-03

    IPC分类号: C21D8/00 C21D9/30 C23C8/26

    摘要: The invention relates to a crankshaft member having high fatigue strength and good bending correctability, and its method of manufacture. The steel made crankshaft member mainly consists of a two-phase structure of ferrite and perlite. The steel includes C, Ni, Mn, and Cr as required elements and Si, Cu, Mo, Ti, V, Nb, Ca, and S as optional elements that may be included, in the amounts of C within the range of 0.20 to 0.50 wt %, Si within the range of 0 to 0.6 wt %, Mn within the range of 0.5 to 1.5 wt %, Cu within the range of 0 to 0.7 wt %, Ni within the range of 0.05 to 1.5 wt %, Cr within the range of 0.05 to 0.45 wt %, and Mo within the range of 0 to 0.5 wt % to satisfy the condition 115≧70C+8Si+23Mn+11Cu+128Cr+83Mo≧50. A portion of the member surface is provided at least with a hard nitride layer having an average hardness within the range of 300 to 450 HV. Lamellar spacing of the perlite is 0.3 μm or less.

    摘要翻译: 本发明涉及具有高疲劳强度和良好的弯曲矫正性的曲轴件及其制造方法。 钢制曲轴构件主要由铁素体和珍珠岩的两相结构组成。 所述钢包含C,Ni,Mn和Cr作为要素,Si,Cu,Mo,Ti,V,Nb,Ca和S作为可以包含的任意元素,C的量在0.20〜 0.50重量%,Si在0〜0.6重量%的范围内,Mn在0.5〜1.5重量%的范围内,Cu在0〜0.7重量%的范围内,Ni在0.05〜1.5重量%的范围内,Cr在 0.05〜0.45重量%的范围,Mo在0〜0.5重量%的范围内,满足条件115≥70℃+ 8Si + 23Mn + 11Cu + 128Cr +83Mo≥50。 构件表面的一部分至少设置有平均硬度在300至450HV范围内的硬质氮化物层。 珍珠岩的层状间隔为0.3μm以下。

    Antagonistic human LIGHT-specific human monoclonal antibodies
    10.
    发明授权
    Antagonistic human LIGHT-specific human monoclonal antibodies 有权
    拮抗人类LIGHT特异性人单克隆抗体

    公开(公告)号:US08461307B2

    公开(公告)日:2013-06-11

    申请号:US13240356

    申请日:2011-09-22

    IPC分类号: C12P21/08

    摘要: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

    摘要翻译: 本文提供了免疫特异性结合于hLIGHT多肽的抗体; 编码抗体的分离的核酸; 载体和宿主细胞,其包含编码抗体的核酸; 制备抗体的方法; 以及治疗受试者中的hLIGHT介导的疾病的方法,包括向受试者施用抗体。 在优选的实施方案中,本文提供的抗hLIGHT抗体可改善,中和或抑制体内的hLIGHT生物活性(例如,hLIGHT介导的来自表达hLIGHT受体的细胞的CCL20,IL-8或RANTES的产生或分泌)。 本文还提供了用于检测样品中的hLIGHT的方法以及用于改善,中和或抑制hLIGHT活性的方法,例如在患有hLIGHT活性有害的病症的人类受试者中。